Proposed Data Collection Submitted for Public Comment and Recommendations, 17604-17606 [2021-06881]
Download as PDF
<![CDATA[
17604
Federal Register / Vol. 86, No. 63 / Monday, April 5, 2021 / Notices
Rhode Island; Southern Nevada Health
District, Nevada; and Tennessee.
The total annual time burden
requested will be reduced by 766 hours
for reasons described below.
• Although the annual number of
restaurants remains the same (n=400),
we have reduced the number of
respondents from ten to five food
workers per restaurant. Thus, the total
number of food workers to be
interviewed is reduced from 4,000 to
2,000 per year.
• The average time burden for food
workers has been reduced from 20
minutes to 17 minutes per response for
recruiting, informed consent, and
interview. Thus, the total time burden
for food workers is reduced from 1,333
to 500 hours per year.
• There are no requested changes to
the number of managers; however, their
time burden has increased by 200 hours
per year. We have transferred the
respondent type for observation from
health department staff in 2018 to the
managers in 2021. Managers incur this
additional time burden by allowing
health department staff to conduct the
observation activities in their
establishments. This change does not
result in any net difference in overall
time burden requested but eliminates
one respondent type.
The total estimated annual burden
requested is 1,011 hours. There is no
cost to the respondents other than their
time.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total burden
(in hours)
Form name
Retail managers ................................
Manager Recruiting Script ...............
Manager Interview/Assessment .......
Observation ......................................
Worker Recruiting Screener and Informed Consent.
Worker Interview/Assessment ..........
889
400
400
2,000
1
1
1
1
3/60
30/60
30/60
2/60
44
200
200
67
2,000
1
15/60
500
...........................................................
........................
........................
........................
1,011
Retail food workers ...........................
Total ...........................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2021–06883 Filed 4–2–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day-2021–21DZ; Docket No. CDC–2021–
0031]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled Harm Reduction Toolkit for NonPrescription Syringe Sales in
Community Pharmacies. The aim of the
SUMMARY:
jbell on DSKJLSW7X2PROD with NOTICES
Number of
respondents
Type of respondents
VerDate Sep<11>2014
17:23 Apr 02, 2021
Jkt 253001
project is to create harm reduction
products that can help: (1) Facilitate
greater access to sterile syringes through
pharmacy-based non-prescription
syringe sales (NPSS), (2) minimize the
burden of NPSS distribution on
pharmacists, and (3) improve pharmacy
personnel’s understanding of, and skills
with, NPSS efforts.
DATES: CDC must receive written
comments on or before June 4, 2021.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2021–
0031 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS–D74, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
Regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
PO 00000
Frm 00019
Fmt 4703
Sfmt 4703
D74, Atlanta, Georgia 30329; phone:
404–639–7118; Email: omb@cdc.gov.
Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected; and
SUPPLEMENTARY INFORMATION:
E:\FR\FM\05APN1.SGM
05APN1
17605
Federal Register / Vol. 86, No. 63 / Monday, April 5, 2021 / Notices
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses.
5. Assess information collection costs.
Proposed Project
Harm Reduction Toolkit for NonPrescription Syringe Sales in
Community Pharmacies—New—
National Center for HIV/AIDS, Viral
Hepatitis, STD and TB Prevention
(NCHHSTP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
Injection drug use, through shared use
of injection equipment, increases risk of
acquiring blood borne pathogens such
as HIV and hepatitis C virus (HCV).
While stopping injection drug use is an
optimal goal for preventing transmission
of bloodborne pathogens among persons
who inject drugs (PWID), it is not
always achievable. However, use of
sterile needles and syringes, for each
injection, can significantly reduce risk
of acquiring bloodborne pathogens and
access to sterile syringes can reduce
needle sharing among PWID.
Community pharmacies are in a
unique position to provide access to
sterile syringes through nonprescription syringe sales (NPSS).
Pharmacies are in this position partly
because they are among the most
accessible of healthcare settings. In fact,
approximately 90% of urban costumers
live within two miles of a pharmacy and
70% of rural costumers are within 15
miles of a pharmacy. Pharmacies also
have extended hours of operations
access to the online training videos for
pharmacists and pharmacy personnel
regarding NPSS and the post-test survey
will be completed in the week following
the one-week training period. An
estimated 60 pharmacy personnel will
complete the pre-test and post-test
surveys. Data from the pre/post-test
surveys will be collected entirely
online. The purpose of the surveys is to
assess pharmacy personnel’s skills and
knowledge pertaining to NPSS before
and after access to the NPSS online
training. Data on pharmacy syringe sales
and service referrals (e.g., referrals for
HIV testing and substance use
treatment) will be collected from each of
the 12 participant pharmacies store or
log records before and after the oneweek training period. Each participant
pharmacy’s manager will conduct a onetime data collection of aggregated
syringe sales and service referrals data
from the 30-day period before and after
the training period. The purpose of
these data is to describe syringe sales
and service referrals before and after
pharmacy personnel’s access to the
NPSS online training. Lastly, one
project director will determine website
usage of the training website and
resource locator for PWID. Training
website usage data will be paired with
the pre-test and post-test surveys and
skill scores and analyzed for
correlations between usage and
knowledge, comfort, and use of NPSS
skills. The numbers of syringe
customers and service referrals and
usage of the resource website for PWID
will be described.
CDC requests OMB approval for an
estimated 73 annual burden hours.
There are no costs to respondents other
than their time.
making them more accessible to
patients. While pharmacies represent
potential sites for NPSS, education and
tools are needed to build pharmacists’
NPSS-related skills and to support
pharmacists in the delivery of NPSS and
other harm reduction services.
The overarching aim of this project is
to create harm reduction products that
can help: (1) Facilitate greater access to
sterile syringes through pharmacy-based
NPSS (2) minimize the burden of NPSS
distribution on pharmacists, and (3)
improve pharmacy personnel’s
understanding of, and skills with, NPSS
efforts. The project will demonstrate
how pharmacy personnel can use a
contractor developed harm reduction kit
for PWID and online training videos for
pharmacy personnel on NPSS, for HIV
prevention.
CDC requests OMB approval to collect
standardized data from an in-field
demonstration and evaluation of three
contractor developed resources for harm
reduction: Harm reduction kit for
persons who inject drugs (PWID); online
training videos for pharmacists and
pharmacy personnel regarding NPSS;
and a resource website for PWID. The
in-field demonstration and evaluation
will take place at 12 project pharmacies
over one six-week period. The
information collection has three primary
components: (1) Online pre-test and
post-test surveys (2) number of
pharmacy syringe sales and service
referrals, and (3) website usage (for the
training website and the resource
website for PWID). Pharmacy personnel
who participate in the in-field
demonstration will complete a one-time
online pre-test survey and a one-time
online post-test survey. The pre-test
survey will be completed in the week
prior to the participants being given
jbell on DSKJLSW7X2PROD with NOTICES
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent
Number of
respondents
Average
burden per
response
(in hours)
Total
burden hours
Type of respondents
Form name
Pharmacists and pharmacy technicians.
Pharmacists and pharmacy technicians.
Pharmacy manager ...........................
Pre-test survey .................................
60
1
30/60
30
Post-test survey ...............................
60
1
30/60
30
12
1
60/60
12
Project director ..................................
Pharmacy syringe sales and service
referrals.
Website usage .................................
1
1
15/60
1
Total ...........................................
...........................................................
........................
........................
........................
73
VerDate Sep<11>2014
17:23 Apr 02, 2021
Jkt 253001
PO 00000
Frm 00020
Fmt 4703
Sfmt 4703
E:\FR\FM\05APN1.SGM
05APN1
17606
Federal Register / Vol. 86, No. 63 / Monday, April 5, 2021 / Notices
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2021–06881 Filed 4–2–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2021–0034]
Advisory Committee on Immunization
Practices (ACIP)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC), announces the
following meeting of the Advisory
Committee on Immunization Practices
(ACIP). This meeting is open to the
public. Time will be available for public
comment. The meeting will be webcast
live via the World Wide Web; for more
information on ACIP please visit the
ACIP website: https://www.cdc.gov/
vaccines/acip/.
DATES: The meeting will be held on June
23–24, 2021, from 9:00 a.m. to 5:30
p.m., EDT (times subject to change).
Written comments must be received on
or before June 24, 2021.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2021–
0034 by any of the following methods:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
MS H24–8, Atlanta, Georgia 30329–
4027, Attn: June ACIP Meeting.
Instructions: All submissions received
must include the Agency name and
Docket Number. All relevant comments
received in conformance with the
https://www.regulations.gov suitability
policy will be posted without change to
https://www.regulations.gov, including
any personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
Written public comments submitted
72 hours prior to the ACIP meeting will
be provided to ACIP members before the
meeting.
FOR FURTHER INFORMATION CONTACT:
Stephanie Thomas, ACIP Committee
jbell on DSKJLSW7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:23 Apr 02, 2021
Jkt 253001
Management Specialist, Centers for
Disease Control and Prevention,
National Center for Immunization and
Respiratory Diseases, 1600 Clifton Road
NE, MS–H24–8, Atlanta, Georgia 30329–
4027; Telephone: (404) 639–8367;
Email: ACIP@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The committee is charged
with advising the Director, CDC, on the
use of immunizing agents. In addition,
under 42 U.S.C. 1396s, the committee is
mandated to establish and periodically
review and, as appropriate, revise the
list of vaccines for administration to
vaccine-eligible children through the
Vaccines for Children (VFC) program,
along with schedules regarding dosing
interval, dosage, and contraindications
to administration of vaccines. Further,
under provisions of the Affordable Care
Act, section 2713 of the Public Health
Service Act, immunization
recommendations of the ACIP that have
been approved by the Director of the
Centers for Disease Control and
Prevention and appear on CDC
immunization schedules must be
covered by applicable health plans.
Matters To Be Considered: The agenda
will include discussions on cholera
vaccine, dengue vaccine, ebola vaccine,
hepatitis vaccines, herpes zoster
vaccines, influenza vaccines,
orthopoxvirus vaccine, pneumococcal
vaccine, rabies vaccine and tickborne
encephalitis vaccine. Recommendation
votes on dengue vaccine, ebola vaccine,
influenza vaccines and rabies vaccine
are scheduled. Vaccines for Children
(VFC) votes on dengue vaccine and
influenza vaccines are scheduled.
Agenda items are subject to change as
priorities dictate. For more information
on the meeting agenda visit https://
www.cdc.gov/vaccines/acip/meetings/
meetings-info.html.
Meeting Information: The meeting
will be webcast live via the World Wide
Web; for more information on ACIP
please visit the ACIP website: https://
www.cdc.gov/vaccines/acip/.
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
PO 00000
Frm 00021
Fmt 4703
Sfmt 9990
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
Oral Public Comment: This meeting
will include time for members of the
public to make an oral comment. Oral
public comment will occur before any
scheduled votes including all votes
relevant to the ACIP’s Affordable Care
Act and Vaccines for Children Program
roles. Priority will be given to
individuals who submit a request to
make an oral public comment before the
meeting according to the procedures
below.
Procedure for Oral Public Comment:
All persons interested in making an oral
public comment at the June 23–24,
2021, ACIP meeting must submit a
request at https://www.cdc.gov/vaccines/
acip/meetings/ no later than 11:59 p.m.,
EDT, June 18, 2021, according to the
instructions provided.
If the number of persons requesting to
speak is greater than can be reasonably
accommodated during the scheduled
time, CDC will conduct a lottery to
determine the speakers for the
scheduled public comment session.
CDC staff will notify individuals
regarding their request to speak by email
by June 21, 2021. To accommodate the
significant interest in participation in
the oral public comment session of
ACIP meetings, each speaker will be
limited to 3 minutes, and each speaker
may only speak once per meeting.
Written Public Comment: The docket
will be opened to receive written
comments on June 1, 2021. Written
comments must be received on or before
June 24, 2021.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–06904 Filed 4–2–21; 8:45 am]
BILLING CODE 4163–18–P
E:\FR\FM\05APN1.SGM
05APN1
]]>Agencies
[Federal Register Volume 86, Number 63 (Monday, April 5, 2021)]
[Notices]
[Pages 17604-17606]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-06881]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-2021-21DZ; Docket No. CDC-2021-0031]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
Federal agencies the opportunity to comment on a proposed and/or
continuing information collection, as required by the Paperwork
Reduction Act of 1995. This notice invites comment on a proposed
information collection project titled Harm Reduction Toolkit for Non-
Prescription Syringe Sales in Community Pharmacies. The aim of the
project is to create harm reduction products that can help: (1)
Facilitate greater access to sterile syringes through pharmacy-based
non-prescription syringe sales (NPSS), (2) minimize the burden of NPSS
distribution on pharmacists, and (3) improve pharmacy personnel's
understanding of, and skills with, NPSS efforts.
DATES: CDC must receive written comments on or before June 4, 2021.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2021-
0031 by any of the following methods:
Federal eRulemaking Portal: Regulations.gov. Follow the
instructions for submitting comments.
Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS-D74, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to Regulations.gov.
Please note: Submit all comments through the Federal eRulemaking
portal (regulations.gov) or by U.S. mail to the address listed above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road NE, MS-D74, Atlanta, Georgia 30329; phone: 404-639-7118; Email:
[email protected].
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
Federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected; and
[[Page 17605]]
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses.
5. Assess information collection costs.
Proposed Project
Harm Reduction Toolkit for Non-Prescription Syringe Sales in
Community Pharmacies--New--National Center for HIV/AIDS, Viral
Hepatitis, STD and TB Prevention (NCHHSTP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
Injection drug use, through shared use of injection equipment,
increases risk of acquiring blood borne pathogens such as HIV and
hepatitis C virus (HCV). While stopping injection drug use is an
optimal goal for preventing transmission of bloodborne pathogens among
persons who inject drugs (PWID), it is not always achievable. However,
use of sterile needles and syringes, for each injection, can
significantly reduce risk of acquiring bloodborne pathogens and access
to sterile syringes can reduce needle sharing among PWID.
Community pharmacies are in a unique position to provide access to
sterile syringes through non-prescription syringe sales (NPSS).
Pharmacies are in this position partly because they are among the most
accessible of healthcare settings. In fact, approximately 90% of urban
costumers live within two miles of a pharmacy and 70% of rural
costumers are within 15 miles of a pharmacy. Pharmacies also have
extended hours of operations making them more accessible to patients.
While pharmacies represent potential sites for NPSS, education and
tools are needed to build pharmacists' NPSS-related skills and to
support pharmacists in the delivery of NPSS and other harm reduction
services.
The overarching aim of this project is to create harm reduction
products that can help: (1) Facilitate greater access to sterile
syringes through pharmacy-based NPSS (2) minimize the burden of NPSS
distribution on pharmacists, and (3) improve pharmacy personnel's
understanding of, and skills with, NPSS efforts. The project will
demonstrate how pharmacy personnel can use a contractor developed harm
reduction kit for PWID and online training videos for pharmacy
personnel on NPSS, for HIV prevention.
CDC requests OMB approval to collect standardized data from an in-
field demonstration and evaluation of three contractor developed
resources for harm reduction: Harm reduction kit for persons who inject
drugs (PWID); online training videos for pharmacists and pharmacy
personnel regarding NPSS; and a resource website for PWID. The in-field
demonstration and evaluation will take place at 12 project pharmacies
over one six-week period. The information collection has three primary
components: (1) Online pre-test and post-test surveys (2) number of
pharmacy syringe sales and service referrals, and (3) website usage
(for the training website and the resource website for PWID). Pharmacy
personnel who participate in the in-field demonstration will complete a
one-time online pre-test survey and a one-time online post-test survey.
The pre-test survey will be completed in the week prior to the
participants being given access to the online training videos for
pharmacists and pharmacy personnel regarding NPSS and the post-test
survey will be completed in the week following the one-week training
period. An estimated 60 pharmacy personnel will complete the pre-test
and post-test surveys. Data from the pre/post-test surveys will be
collected entirely online. The purpose of the surveys is to assess
pharmacy personnel's skills and knowledge pertaining to NPSS before and
after access to the NPSS online training. Data on pharmacy syringe
sales and service referrals (e.g., referrals for HIV testing and
substance use treatment) will be collected from each of the 12
participant pharmacies store or log records before and after the one-
week training period. Each participant pharmacy's manager will conduct
a one-time data collection of aggregated syringe sales and service
referrals data from the 30-day period before and after the training
period. The purpose of these data is to describe syringe sales and
service referrals before and after pharmacy personnel's access to the
NPSS online training. Lastly, one project director will determine
website usage of the training website and resource locator for PWID.
Training website usage data will be paired with the pre-test and post-
test surveys and skill scores and analyzed for correlations between
usage and knowledge, comfort, and use of NPSS skills. The numbers of
syringe customers and service referrals and usage of the resource
website for PWID will be described.
CDC requests OMB approval for an estimated 73 annual burden hours.
There are no costs to respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per Total burden
Type of respondents Form name respondents responses per response (in hours
respondent hours)
----------------------------------------------------------------------------------------------------------------
Pharmacists and pharmacy Pre-test survey. 60 1 30/60 30
technicians.
Pharmacists and pharmacy Post-test survey 60 1 30/60 30
technicians.
Pharmacy manager.............. Pharmacy syringe 12 1 60/60 12
sales and
service
referrals.
Project director.............. Website usage... 1 1 15/60 1
---------------------------------------------------------------
Total..................... ................ .............. .............. .............. 73
----------------------------------------------------------------------------------------------------------------
[[Page 17606]]
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2021-06881 Filed 4-2-21; 8:45 am]
BILLING CODE 4163-18-P
